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Reply
We appreciate the commentary provided by Dr Mackey and
Professor Naylor on the ARCHeR publication and the opportunity
to respond.
Professor Naylor commends us on “being the only one of the
10 or so ‘high-risk’ [sic] stent registries to publish” results, and
although we appreciate the salute, we refer Professor Naylor to the
publication of the CREATE trial by Safian et al1 several months
ago, and we know of at least one other study currently in review. As
a point of clarification, there have been seven high-surgical-risk
registries completed in the United States since the advent of
embolic protection devices.
Two specific issues are raised by Professor Naylor, one con-
cerning statistical methodology and the other the clinical applica-
bility of results. Regarding methodology, the noninferiority design
is increasingly common where the intent is to establish a reasonable
technology or technique alternative to an existing therapy (which
may be preferred because of less invasiveness or cost, greater
availability, and so on) and where previous literature exists to
establish a control rate.2 In addition, noninferiority trial designs are
generally preferred over equivalence trials, which are unnecessarily
two tailed. In the case of carotid stenting in the United States,
randomization in high-surgical-risk trials was believed to likely
hinder timely enrollment (as evidenced by the SAPPHIRE trial),
so this alternative study design was established.
Both Professor Naylor and Dr Mackey question various com-
ponents of and/or methods used for the comparator—specifically,
the weighted historical control. This information was not included
in our original article because of space constraints. To be clear, the
methodology for the determination of a weighted historical con-
trol was established a priori in a binding contract with the Food
and Drug Administration before the first patient was enrolled in
ARCHeR. Once the last patient was enrolled, the 14.4% compar-
ator was computed from the prespecified 1-year composite end
point rates, which were 15% for comorbid conditions and 11% for
anatomic conditions, and weighted according to the actual distri-
bution in those categories. Although we appreciate Professor
Naylor’s concern with stopped trials,3 as explained in the text of
the article, ARCHeR 1 was rolled over into ARCHeR 2 to allow for
the introduction of the embolic protection filter and not for clinical
or outcome reasons; it did not complete enrollment by agreement
with the overseeing regulatory body. Moreover, all three phases of
the trial were conducted with the same inclusion and exclusion
criteria, which resulted not only in their poolability, but also in a
homogeneous distribution of symptomatic patients across three trials.
Both Professor Naylor and Dr Mackey go to great lengths
to prove that the concept of a high-surgical-risk patient is a
fallacy. It is unfortunate that leaders in the field in vascular surgery
continue to beat this drum, providing in support only retrospective
data from single surgeons or centers, all of which lack both
rigorous neurologic audit and 30-day follow-up, which have be-
come the standard for assessing carotid stent procedural outcomes.
Previous studies have clearly demonstrated a threefold increase in
apparent stroke rates with prospective neurologic evaluation, as
was performed in ARCHeR.4,5 What is not offered is the contem-
porary outcomes in a very similar endarterectomy cohort in the
SAPPHIRE trial,6 in which the 1-year composite end point in the
surgical group was 20.1% and higher than the randomized stent
cohort at every time point.
More recently, the generalizability of these results in the nontrial
setting has been demonstrated in the subsequent CAPTURE registry
(TCT 2006 Scientific Sessions, oral presentation. October 2006),
in which the 30-day rates of adverse outcomes in more than 3500
patients tracked with neurologic audit are lower than these AR-
CHeR results. In contrast, real-world mortality rates with carotid
endarterectomy have been reported to be nearly three times higher
than those in landmark clinical trials.7
Any attempt to compare data from the ARCHeR trials with a
normal-surgical-risk historical cohort will be missing the point.
High-surgical-risk patients not only are at increased risk for end-
arterectomy, but are also likely to be at increased risk for stroke as
well. Data from the Asymptomatic Carotid Stenosis and Risk of
Stroke group confirm that the existence of even two comorbid
factors (contralateral transient ischemic attack and renal insuffi-
ciency) are associated with an increase in the 1-year event rate from
2.3% to 7.3% in patients with carotid disease.8
The field of vascular surgery has had more than 50 years of
experience with endarterectomy, yet it has failed to conduct a
single study vs medical therapy among high-surgical-risk candi-
dates. Nonetheless, large numbers of individuals at high surgical
risk undergo endarterectomy each year. It seems, then, somewhat
disingenuous to suggest that carotid stenting, which compares
favorably to surgery in this population, should be discarded as a
therapeutic option because it has not proven any effectiveness vs
medical therapy. We nonetheless agree with Dr Mackey that fur-
ther study of these two therapies with both prospective neurologic
evaluation and long-term follow-up will help define the need for,
and utility of, carotid revascularization in this population.
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Regarding “InterGard silver bifurcated graft:
Features and results of a multicenter study”
Ricco1 recently published an article containing a meta-
analysis but did not describe the techniques of the analysis. The
absence of methodology stimulates the following questions:
What were the inclusion/exclusion criteria for selection of the
comparator studies? As presented, it is impossible to reproduce
the meta-analysis or, more importantly, discern the effect of
various biases.2,3 How robust was the conclusion from the
meta-analysis when possible confounding factors were consid-
ered? Various types of bias are inherent within any meta-
analysis. It is a basic necessity of all meta-analyses to perform
sensitivity analyses to demonstrate the robustness of results.4,5
Did the studies in the meta-analysis report graft infection in
terms of odds ratios, or did the authors extrapolate these data
from reported percentages and counts? Translation of percent-
age and count data directly into an odds ratio without account-
ing for differences in follow-up duration between individual
studies would introduce statistical bias. Moreover, the authors
fail to state whether individual study data were weighted to
derive the combined odds ratio and did not describe the calcu-
lation method used: either fixed-effect or random-effect mod-
eling.3 Do the wide confidence intervals for the odds ratio of the
author’s study (0.21 with a 95% confidence interval of 0.01-4.4)
really reflect a reproducible outcome? The dashed vertical line in
their Forrest plot (fig 6)1 corresponds to no effect (odds ratio
1.0). If the confidence interval of individual studies includes 1,
then it is debatable whether any difference in the effect estimate
of one treatment vs another is significant at conventional levels
(P  .05). Finally, did the authors consider the homogeneity vs
heterogeneity of individual studies used? The poolability of
individual study data in the meta-analysis was not discussed,
although the data in the Forrest plot (fig 6)1 suggest that
individual study data were homogeneous. Consequently, we
believe that the authors should have commented on the appli-
cability of their conclusion toward patient populations with
characteristics (eg, comorbidities and risk factors) that are dif-
ferent from the patient populations considered.5
This postmarketing study has a commendable data return,
considering its study type and follow-up duration, with just 2.8%
patients lost to follow-up over a mean of 55 months.1 Complete
disposition of all patients from all centers through each study
period would have been useful. Kaplan-Meier curves with a 3-year
follow-up are presented despite a reported mean follow-up longer
than 4.5 years. The low attrition rate and follow-up duration
suggest that data are available to show outcomes well beyond the
selected follow-up of 3 years. A rationale for limiting the survival
data to 3 years would be appropriate.
There are remarkably few English-language publications on
the use of silver-coated bifurcated vascular grafts.1,6 Answers to the
above methodologic and reporting issues would allow readers to
better judge the validity of the stated conclusions.
Stephen A. O’Connor, PhD, Hon FRCP
4 The Green
Bedfordshire, United Kingdom
Peter Andrew, MMedSci, PhD
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Reply
We appreciate the letter from O’Connor and Andrew con-
cerning our article, but we want to clarify the following points
concerning the methodology of the study and the meta-analysis
presented in the article.
The purpose of our prospective multicenter study was to
evaluate the safety, patency, and infection rate of a bifurcated aortic
polyester graft coated with collagen and silver acetate. As pointed
out by O’Connor and Andrew, our study had only 2.8% of patients
lost to follow-up over a mean of 55 months. This result was
achieved by adequate monitoring of all centers. In addition, uni-
formity and completeness in complication reporting was verified
during on-site monitoring visits by comparing complications in
charts with those in the case-report form. As usual, the Kaplan-
Meier curves were used to report patient survival and primary and
secondary patency up to 3 years. As pointed out by O’Connor and
Andrew, follow-up was longer for some patients, and technically
any survival plot can be extended right through to the longest
follow-up time. However, this extension is not good statistical
practice, because for any such plot the eye is drawn to the right (ie,
where the plot finishes), where there is least information and
greatest uncertainty. Much of the right-hand part of the plot can
Fig. Funnel plots with graft infection log odds ratios from indi-
vidual studies on the horizontal axis and standard error reflecting
the study size on the vertical axis. The name funnel plot is based on
the fact that the precision in the estimation of graft infection will
increase as the sample size of component studies increases. Effect
estimates from small studies will therefore scatter more widely at
the bottom of the graph, with the spread narrowing among larger
studies. In the absence of bias, as shown here with data from our
studies, the plot will resemble a symmetrical inverted funnel.
JOURNAL OF VASCULAR SURGERY
January 2007224 O’Connor and Andrew
